Herpes Zoster News and Research

RSS
Herpes Zoster, also called shingles, is a painful skin rash caused by the varicella-zoster virus, the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains inactive in the body. Usually the virus does not cause any further problems; however, the virus may re-emerge years later, causing shingles.
Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

Vaccinating older adults against shingles is likely cost-effective in Canada

Vaccinating older adults against shingles is likely cost-effective in Canada

New shingles vaccine reduces outbreaks of painful rash among stem cell transplant patients

New shingles vaccine reduces outbreaks of painful rash among stem cell transplant patients

Oral steroid use in patients with inflammatory diseases increases risk of infection

Oral steroid use in patients with inflammatory diseases increases risk of infection

Chickenpox vaccine lessens likelihood of pediatric shingles

Chickenpox vaccine lessens likelihood of pediatric shingles

Study shows high incidence of herpes zoster ophthalmicus among older adults

Study shows high incidence of herpes zoster ophthalmicus among older adults

Scientific evidence for and against causal associations for 47 adverse effects after immunization

Scientific evidence for and against causal associations for 47 adverse effects after immunization

Space worries - shingles affecting astronauts says NASA

Space worries - shingles affecting astronauts says NASA

Having vaccine after shingles appear do not reduce the risk of stroke

Having vaccine after shingles appear do not reduce the risk of stroke

Cancer patients have greater risk of developing shingles, study shows

Cancer patients have greater risk of developing shingles, study shows

Newer vaccine far more successful in preventing shingles, systematic review reveals

Newer vaccine far more successful in preventing shingles, systematic review reveals

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

AbbVie’s U-ACHIEVE Phase 2b/3 dose-ranging study improves outcomes in patients with ulcerative colitis

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

AJMC addresses role of community pharmacies in boosting adult vaccination rates

AJMC addresses role of community pharmacies in boosting adult vaccination rates

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA